Guolian Securities: Increased attention to tumor immunology, recommend focusing on targeted drugs such as PD1/IL2 in pharmaceutical companies.
With the increasing attention to tumor immunity, and the successive launch of advantageous products, bullish on PD1/IL2 and PD1/IL15 targeted drugs.
Home Depot To Rally More Than 14%? Here Are 10 Top Analyst Forecasts For Monday
JP Morgan Maintains Overweight on IQVIA Hldgs, Raises Price Target to $288
IQVIA Hldgs Analyst Ratings
Does IQVIA Holdings (NYSE:IQV) Deserve A Spot On Your Watchlist?
Express News | IQVIA Holdings Inc : JP Morgan Raises Target Price to $288 From $260
Express News | Morgan Stanley Wealth Management Removes Position in Halliburton Co
Express News | Morgan Stanley Wealth Management Increases Internally Held Portfolio Weights in Spotify Technology, Pinterest, Chewy
Express News | Morgan Stanley Wealth Management Removes Position in S&P Global Inc
Express News | Morgan Stanley Wealth Management Reduces Position in Iqivia Holdings Inc
Express News | Morgan Stanley Wealth Management Increases Position in Nvidia Corp
Express News | Morgan Stanley Wealth Management Adds Position in Teradyne Inc
Express News | Morgan Stanley Wealth Management Adds Position in Cadence Design Systems Inc
Express News | Morgan Stanley Wealth Management Tweaks Holdings in Its U.S. All Cap Growth Model Portfolio
IQVIA Holdings Inc.'s (NYSE:IQV) High Institutional Ownership Speaks for Itself as Stock Continues to Impress, up 6.0% Over Last Week
Argus Research Maintains IQVIA Holdings(IQV.US) With Buy Rating
IQVIA Holdings (IQV) Receives a Buy From Argus Research
IQVIA Holdings Inc. (NYSE:IQV) Is Largely Controlled by Institutional Shareholders Who Own 89% of the Company
IQVIA Holdings Insiders Sold US$9.2m Of Shares Suggesting Hesitancy
Stifel Maintains IQVIA Holdings(IQV.US) With Buy Rating, Raises Target Price to $312